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Figure S1 – S11 1H NMR and 13C NMR spectra of synthesized complexes recorded in DMSO-
d6and CD3OD-d4 
Figure S12. Representative cell survival curves of (A) HCC1937, (B) MDA-MB-231, (C) MDA-
MB-453, (D) MCF-7, and (E) MDA-MB-361 cells after 72 h of treatment with ruthenium 
complexes (C1-C4), ruthenium(II)-arenes (C5, C6), and ligands (L1, L2). 
Figure S13. Photomicrographs of (A) MCF-7 and (B) MDA-MB-231 control cells and cells 
exposed to 400 µM and 800 µM ruthenium complexes (C1-C4) for 72 h. Cells were observed 
under the bright filed inverted microscope, using the 80x/0.2 objective. 
Figure S14. Flow cytometric analysis of the HCC1937 cell cycle phase distribution in response to 
the 72 h treatment with 500 µM ruthenium complexes (C1-C4), ruthenium(II)-arenes (C5, C6), 
and ligands (L1, L2), or with 5 µM and 10 µM CDDP. Histograms presenting DNA content (x-














Figure S1.1H NMR spectrum of complex C1 recorded in DMSO-d6 
 
Figure S2.13C NMR spectrum of complex C1 recorded in DMSO-d6 
 
Figure S3.1H NMR spectra of aromatic part of C1 (red line)overlapped with the ligand L1 (blue 
line), recorded in DMSO-d6.  
 
Figure S4.1H NMR spectrum of complex C2 recorded in CD3OD-d4 
 
Figure S5.13C NMR spectrum of complex C2 recorded in CD3OD-d4 
 
Figure S6.1H NMR spectra ofaromatic part of C2 (blue line)overlapped with the ligand L1 (red 
line), recorded in CD3OD-d4.  
 
Figure S7.1H NMR spectrum of complex C3 recorded in DMSO-d6 
 
Figure S8.13C NMR spectrum of complex C3 recorded in DMSO-d6 
 
Figure S9.1H NMR spectrum of complex C4 recorded in DMSO-d6 
 
Figure S10.13C NMR spectrum of complex C4 recorded in DMSO-d6 
 
Figure S11.Time dependence1H NMR spectrum of complex C3 recorded in DMSO-d6 
 
 
Figure S12. Representative cell survival curves of (A) HCC1937, (B) MDA-MB-231, (C) MDA-
MB-453, (D) MCF-7, and (E) MDA-MB-361 cells after 72 h of treatment with ruthenium 
complexes (C1-C4), ruthenium(II)-arenes (C5, C6), and ligands (L1, L2). 
 
 
Figure S13. Photomicrographs of (A) MCF-7 and (B) MDA-MB-231 control cells and cells 
exposed to 400 µM and 800 µM ruthenium complexes (C1-C4) for 72 h. Cells were observed 
under the bright filed inverted microscope, using the 80x/0.2 objective. 
 
Figure S14. Flow cytometric analysis of the HCC1937 cell cycle phase distribution in response to 
the 72 h treatment with 500 µM ruthenium complexes (C1-C4), ruthenium(II)-arenes (C5, C6), 
and ligands (L1, L2), or with 5 µM and 10 µM CDDP. Histograms presenting DNA content (x-
axis: PI fluorescence) versus cell counts (y-axis) are representative of at least two independent 
experiments.  
 
